文献速递糖尿病肥胖与代谢综合征

氯沙坦在大鼠糖尿病相关抑郁模型中的新治疗潜力与BDNF信号改变平行

Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling.
PubMed 文献 · Diabetologia · 2019-05-03

该研究在链脲佐菌素诱导的成年雄性Wistar大鼠糖尿病模型中,于糖尿病5周后以非降压口服剂量氯沙坦20 mg/kg治疗2周。结果显示糖尿病大鼠出现抑郁样行为,氯沙坦可逆转该行为,其作用通过改变糖尿病诱导的神经炎症反应而非脑灌注,并恢复星形胶质细胞BDNF产生、促进BDNF-TrkB-CREB信号。

要点

  • 氯沙坦可逆转糖尿病大鼠的抑郁样行为
  • 作用机制涉及神经炎症而非脑灌注改变
  • 氯沙坦恢复星形胶质细胞BDNF并促进TrkB-CREB信号

核心结论

  • 氯沙坦在神经系统具有新效应,可能用于缓解糖尿病相关抑郁症状。
  • ARB可能作为潜在抗抑郁药,BDNF可能是糖尿病诱导并发症的未来药物开发靶点。

研究设计与样本

  • 研究为实验性大鼠研究,糖尿病由链脲佐菌素诱导于成年雄性Wistar大鼠。
  • 糖尿病5周后以非降压口服剂量氯沙坦20 mg/kg治疗2周。
  • 方案1用单光子发射计算机断层扫描-MRI和免疫组化评估脑血管灌注与胶质激活。
  • 方案2进行强迫游泳实验和旷场实验等行为学研究,并评估海马促炎反应与BDNF信号。

主要发现

  • 糖尿病大鼠表现出抑郁样行为,氯沙坦可治疗性逆转该行为。
  • 氯沙坦的作用通过改变糖尿病诱导的神经炎症反应实现,而非改变脑灌注。
  • 氯沙坦恢复糖尿病大脑星形胶质细胞中BDNF的产生,并促进BDNF-原肌球蛋白受体激酶B-cAMP反应元件结合蛋白信号。

临床怎么用

  • 提示ARB氯沙坦在糖尿病相关抑郁中可能具有超出降压的神经保护与抗抑郁潜力。
  • BDNF信号可作为糖尿病诱导并发症的潜在干预靶点。

局限性

  • 研究为动物实验,结果向临床转化需进一步验证。
  • 仅使用成年雄性Wistar大鼠,未涵盖性别差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin-angiotensin-aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we investigated the antidepressant effect and the mechanisms of action of the angiotensin receptor 1 blocker (ARB) losartan in an experiential model of diabetes-associated depression. METHODS: Experimental diabetes was induced by streptozotocin in adult male Wistar rats. After 5 weeks of diabetes, rats were treated for 2 weeks with a non-pressor oral dose of losartan (20 mg/kg). In protocol 1, cerebrovascular perfusion and glial activation were evaluated by single-photon emission computed tomography-MRI and immunohistochemistry. In protocol 2, behaviour studies were performed (forced swim test and open field test). Hippocampal proinflammatory response and brain-derived neurotrophic factor (BDNF) signalling were also assessed. RESULTS: Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan. This action of losartan occurs via changes in diabetes-induced neuroinflammatory responses rather than altered cerebral perfusion. We also show that as a part of its protective effect losartan restores BDNF production in astrocytes and facilitates BDNF-tropomyosin receptor kinase B-cAMP response element-binding protein signalling in the diabetic brain. CONCLUSIONS/INTERPRETATION: We identified a novel effect of losartan in the nervous system that may be implemented to alleviate symptoms of diabetes-associated depression. These findings explore a new therapeutic horizon for ARBs as possible antidepressants and suggest that BDNF could be a target of future drug development in diabetes-induced complications.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lenart L, Balogh DB, Lenart N, et al. Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling. Diabetologia. 2019. PMID: 31053872. doi:10.1007/s00125-019-4888-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。